MDACC Study No:2011-0816 ( NCT No: NCT01489722)
Title:A Phase Ia/Ib, Open-Label, Multicentre, Two-Part Study to Assess the
Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208
Administered Daily in Adult Patients with Recurrent or Refractory Acute
Myelogenous Leukemia (AML)
Principal Investigator:Jorge Cortes
Treatment Agent:AZD1208
Study Status:Terminated
Study Description:The goal of Part 1 of this clinical research study is to find the highest
tolerable dose of AZD1208 that can be given to patients with AML.

The goal of Part 2 of this study is to learn if AZD1208 can control AML. The
safety of this drug will also be studied in both parts.

AZD1208 is designed to stop the growth of abnormal white blood cells. This may
help to control AML. This is the first study using AZD1208 in humans.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I
Treatment Agents:AZD1208
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:AstraZeneca Pharmaceuticals LP
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jorge Cortes
For Clinical Trial Enrollment:713-794-5783
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults